Menu
Not yet recruiting NCT07722845

Illness Perception and Treatment Expectations in Lateral Elbow Pain

Observational Lateral Elbow Pain Lateral Epicondylitis Tennis Elbow Chronic Musculoskeletal Pain

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Lateral Elbow Pain, Lateral Epicondylitis, Tennis Elbow, Chronic Musculoskeletal Pain. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Turkey (Türkiye)
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Determining the Predictors of Illness Perception and Treatment Expectations in Individuals With Lateral Elbow Pain: A Cross-Sectional Study

Overview

This cross-sectional, correlational study aims to determine the predictors of illness perception and treatment expectations in adults with chronic lateral elbow pain. Sociodemographic characteristics, clinical findings (pain intensity, pain duration, elbow-specific function) and psychosocial variables (pain self-efficacy, fear-avoidance beliefs, pain catastrophizing) will be examined as candidate predictors of two patient-centred constructs: illness perception, measured with the Brief Illness Perception Questionnaire, and treatment expectation, measured with the Treatment Expectation Questionnaire. Data will be analysed using hierarchical multiple linear regression in three predictor blocks. The study is reported according to the STROBE statement.

Primary outcome measures

  • Illness perception (Brief Illness Perception Questionnaire, B-IPQ) [Time frame: Single assessment at enrollment (Day 1)]
  • Treatment expectation (Treatment Expectation Questionnaire, TEX-Q) [Time frame: Single assessment at enrollment (Day 1)]
Secondary outcome measures (5)
  • Pain intensity (Numeric Rating Scale, NRS) [Time frame: Single assessment at enrollment (Day 1)]
  • Pain self-efficacy (Pain Self-Efficacy Questionnaire, PSEQ) [Time frame: Single assessment at enrollment (Day 1)]
  • Fear-avoidance beliefs (Fear-Avoidance Beliefs Questionnaire, FABQ) [Time frame: Single assessment at enrollment (Day 1)]
  • Pain catastrophizing (Pain Catastrophizing Scale, PCS) [Time frame: Single assessment at enrollment (Day 1)]
  • Elbow pain and function (Patient-Rated Tennis Elbow Evaluation, PRTEE) [Time frame: Single assessment at enrollment (Day 1)]

Eligibility criteria

Inclusion criteria

  • Aged 18 years or older
  • Diagnosis of lateral epicondylalgia or lateral elbow pain made by an orthopaedic surgeon or physiatrist
  • Pain intensity of at least 4 on the Numeric Rating Scale
  • Pain duration of at least 12 weeks (chronic)
  • Willing to provide written informed consent

Exclusion criteria

  • History of any surgical procedure of the upper extremity
  • Cervical spine pathology
  • Inflammatory arthritis affecting the wrist or finger joints (e.g. rheumatoid arthritis)
  • Active neurological disease or radiculopathy radiating to the upper extremity
  • Diagnosis of fibromyalgia or another widespread pain syndrome
  • Currently receiving active psychiatric treatment (e.g. psychosis, severe depression)
  • Pregnancy
  • Visual or cognitive impairment of a degree that would prevent completion of the questionnaires

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Turkey (Türkiye) · 1 center
  • Dr. Fzt. Fatih Celik Ozel Saglik Birimi — Istanbul

Identifiers

NCT: NCT07722845 · AcibademHG1

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗